Form 4: Progyny CPO Clapp Receives Equity Grants

Progyny's Chief Product Officer, Geoffrey Clapp, was granted 35,228 restricted stock units and 51,373 stock options as part of an annual merit award.

Summary

• Chief Product Officer Geoffrey Clapp received an annual merit grant of 35,228 Restricted Stock Units (RSUs) on March 2, 2026.
• Clapp also received an annual merit grant of 51,373 stock options with an exercise price of $17.60 on March 2, 2026.
• Both grants were made pursuant to Progyny's 2019 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock, with 33% vesting on the first anniversary of the grant date and the remainder vesting quarterly through the third anniversary, subject to continued service.
• The stock options also vest 33% on the first anniversary of the grant date, with the remainder vesting quarterly through the third anniversary, subject to continued service.
• Following these transactions, Clapp beneficially owns 63,922 shares of common stock and 51,373 derivative stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine, slightly positive event, reflecting ongoing executive compensation and retention efforts, which aligns management's interests with long-term company performance.

Positives

• The equity grants align the Chief Product Officer's interests with long-term shareholder value through multi-year vesting schedules.
• These grants serve as a common incentive for retaining key executives and motivating sustained performance.

Future Outlook

The vesting schedules for the RSUs and stock options extend through the third anniversary of the grant date, indicating a long-term retention strategy for the Chief Product Officer and an incentive for sustained performance.

Industry Context

StockSavvy.ai notes that equity grants to key executives like a Chief Product Officer are standard practice in the technology and healthcare services sectors, particularly for growth-oriented companies like Progyny, to incentivize long-term performance and retain talent in a competitive market.

Comparison to Industry Standards

• Multi-year vesting schedules (e.g., 3 years) for executive equity grants are common across industries, including healthcare technology, aligning with best practices for executive retention and performance incentives.
• Companies like Teladoc Health (TDOC) and Livongo (now part of Teladoc) have historically utilized similar long-term equity incentive structures for their leadership teams to foster commitment and align with shareholder interests.

Related Party Transactions

• The grants of Restricted Stock Units and stock options to Chief Product Officer Geoffrey Clapp constitute related party transactions as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• Vesting of 33% of RSUs and stock options on the first anniversary of the grant date (March 2, 2027).
• Subsequent quarterly vesting installments through the third anniversary of the grant date (March 2, 2029).

Key Dates

Recommendation

This Form 4 filing details routine equity grants to a key executive, which is a standard practice for executive compensation and retention. It does not present new information that would fundamentally alter the investment thesis for Progyny, hence a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific filing.

Keywords

Progyny, PGNY, Geoffrey Clapp, Chief Product Officer, CPO, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Insider Ownership, Executive Compensation, Form 4, SEC Filing